Original Article
Efficacy and safety of albumin-bound paclitaxel in the treatment of advanced malignant tumors
Li Wenwen, Han Lei, Zhang Zhiguo, Li Li, Guo Hongwei, Xun Pei, Luo Jian
Published 2019-12-20
Cite as J Chin Physician, 2019,21(12): 1803-1807. DOI: 10.3760/cma.j.issn.1008-1372.2019.12.012
Abstract
ObjectiveTo investigate the efficacy and safety of albumin-bound paclitaxel in the treatment of advanced malignant tumors.
MethodsPatients in advanced stage of cancer who had had drug-resistant relapse after receiving multiple-line treatment received chemotherapy with albumin-bound paclitaxel from May 2016 to April 2018 in Daxing Hospital of Capital Medical University. Their clinical data were collected to evaluate the treatment efficacy and safety profile.
Results36 patients who had advanced treatment-resistent tumors with evaluable data were enrolled. Of 36 patients, 55.56% (20) had previously received chemotherapy with paclitaxel. The objective response rate (ORR) was 8.33%, the disease control rate (DCR) was 25.0%, the median progression free survival (PFS) was 106 days, and the median overall survival (OS) was 183 days. The main adverse reactions of grade 3-4 were hematological toxicity, including neutropenia [36.11% (13/36)], anemia and thrombocytopenia [5.56% (2/36) and 16.67% (6/36)] in patients without neutropenia fever. Adverse effects of 3-4 degrees related to non-hematologic toxicity were not observed.
ConclusionsChemotherapy regimen with albumin-bound paclitaxel has certain efficacy for advanced malignant tumors resistant to multiple lines of therapy and the adverse effects could be generally tolerated.
Key words:
Albumin-bound paclitaxel; Antineoplastic combined chemotherapy protocols; Drug resistance, neoplasm
Contributor Information
Li Wenwen
Department of Oncology, Daxing Hospital of Capital Medical University, Beijing 102600, China
Han Lei
Department of Oncology, Daxing Hospital of Capital Medical University, Beijing 102600, China
Zhang Zhiguo
Department of Oncology, Daxing Hospital of Capital Medical University, Beijing 102600, China
Li Li
Department of Oncology, Daxing Hospital of Capital Medical University, Beijing 102600, China
Guo Hongwei
Department of Oncology, Daxing Hospital of Capital Medical University, Beijing 102600, China
Xun Pei
Department of Oncology, Daxing Hospital of Capital Medical University, Beijing 102600, China
Luo Jian
Department of Oncology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College (PUMC), Cancer Hospital, Beijing 100021, China
